CSIMarket Company Name, Ticker, Customers, else..
 
Science 37 Holdings Inc   (NASDAQ: SNCE)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 118
 Employees 550
 Revenues (TTM) (Millions $) 60
 Net Income (TTM) (Millions $) -111
 Cash Flow (TTM) (Millions $) -52
 Capital Exp. (TTM) (Millions $) 26

Business Description


Science 37 Holdings Inc is a healthcare technology and clinical research company based in the United States. It offers a virtual clinical trial platform that allows patients to participate in medical research studies remotely, eliminating the need for physical visits to research centers. The company aims to increase the efficiency and convenience of clinical trials, ultimately accelerating medical research and development. It partners with pharmaceutical companies, academic institutions, and government organizations to conduct a wide range of studies across various therapeutic areas. Science 37 Holdings Inc utilizes telemedicine, mobile technology, and data analytics to collect and analyze patient data, ensuring accurate and reliable results.


   Company Address: 800 Park Offices Drive Research Triangle Park 27709 NC
   Company Phone Number: 377-3737   Stock Exchange / Ticker: NASDAQ SNCE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ICLR        2.49% 
LH   -4.27%    
MEDP        0.88% 
CLAR   -1.96%    
• View Complete Report
   



Clinical Study

Pioneering Digital Trials Science 37s Impact on GSKs Phase 3 Rare Disease Research

Published Thu, Nov 21 2024 1:00 PM UTC

The landscape of clinical trials is undergoing a transformative shift fueled by innovative digital strategies. This change is exemplified by Science 37 s remarkable contribution to GlaxoSmithKline s (GSK) Phase 3 rare disease trial. Recent announcements reveal that Science 37 nearly doubled the U.S. enrollment and contributed almost half of the participants in this critical ...
Product Service News

Science 37 Pioneering the Future of Decentralized Clinical Trials

Published Mon, Sep 16 2024 12:01 PM UTC

In a significant milestone for the decentralized clinical trials (DCT) landscape, Science 37 has been awarded the 2024 Global Company of the Year Award by Frost & Sullivan. This honor not only underscores Science 37’s position as an industry leader but also highlights the growing importance of decentralized methodologies in clinical research. The award recognizes key attri...
Management Announcement

Catalyzing Next-Generation Clinical Research: Science 37's Revolution in North Carolina's Research Triangle Park

Published Tue, Aug 6 2024 12:00 PM UTC

Science 37 Reinforces Clinical Trial Innovations with Cutting-Edge Research Facility in North Carolina s Research Triangle Park
In a groundbreaking move for the clinical research industry, Science 37 has unveiled its new corporate headquarters in Research Triangle Park, North Carolina. This state-of-the-art facility aims to revolutionize the way clinical trials are condu...
Management Announcement

The Remarkable Success Story of Science 37: Fast Enrollment Rates and Impressive ROI

Published Thu, Jul 18 2024 12:00 PM UTC


In the competitive world of clinical trials and healthcare research, one company has emerged as a standout performer. Science 37 Holdings Inc, a leader in decentralized clinical trials, has recently achieved some remarkable milestones that have caught the attention of both industry experts and investors.
Firstly, Science 37 proudly announced that it successfully enr...
Product Service News

Science 37 Accelerating Patient Recruitment and Enrollment in Clinical Trials

Published Thu, Jun 27 2024 1:41 PM UTC

In an era where medical research and innovation are vital for advancing healthcare, clinical trials play a crucial role in bringing new therapies and treatments to patients. One persistent challenge in conducting clinical trials has been the slow recruitment and enrollment of participants. However, Science 37, a pioneering company, has emerged as a game-changer in this aspec...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.76
Working Capital Ratio 5.03
Leverage Ratio (MRQ) 0.4
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.07 $
Revenues (TTM) 0.51 $
Cash Flow (TTM) -
Cash 0.48 $
Book Value 0.44 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 109,565
Net Income per Employee (TTM) -201,325
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.57

Profitability Ratios Current
Gross Margin (MRQ) 39.73 %
Operating Margin (MRQ) -97.7 %
Net Margin (MRQ) -0.01 %
Net Cash Flow Margin (MRQ) -57.74 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.